亚安培南西司他丁与莫西沙星联用治疗老年重症肺炎的临床效果  

Clinical Effect of Combination of Imipenem and Cilastatin and Moxifloxacin in the Treatment of Severe Pneumonia in the Elderly

作　　者：韩艳芳 HAN Yanfang(Lingyuan Central Hospital,Lingyuan 122500,China)

机构地区：[1]辽宁省凌源市中心医院,辽宁凌源122500

出　　处：《中国医药指南》2023年第6期84-86,共3页Guide of China Medicine

摘　　要：目的 研究亚安培南、西司他丁与莫西沙星这一联合治疗方案对老年重症肺炎患者进行治疗的效果,以进一步提升临床治疗疗效。方法 试验选取了2019年1月至2019年12月收治的老年重症肺炎患者作为研究的对象。通过回顾式分析对68例患者采用数字随机分组法,以公平性开展为前提进行分组调查。对照组患者采用常规抗生素治疗措施,观察组则为亚安培南、西司他丁与莫西沙星联合方案,分析应用成效和治疗安全性。结果 从治疗质量上看,观察组患者的治疗总有效率为91.18%,对照组为79.41%,组间对比差异较为显著,具有统计学意义(P <0.05)。与此同时,在住院时间上,观察组用时为(10.20±3.10)d,对照组则为(15.60±4.20)d,差异具有统计学意义(P <0.05)。此外,对比了患者的肝肾功能的变化情况,即在治疗后观察组患者的丙氨酸氨基转移酶和血肌酐水平分别为(34.49±6.55)U/L和(81.45±16.14)μmol/L,而对照组患者则为(33.85±5.42)U/L和(82.49±15.49)μmol/L,差异不具有统计学意义(P> 0.05)。在白细胞计数、血清C反应蛋白以及降钙素原指标的统计上,观察组患者的改善效果优于对照组,对比差异显著(P <0.05)。最后,在不良反应事件的调查上,观察组患者的发生率为2.94%(1/34),明显优于对照组的8.82%(3/34),差异具有统计学意义(P <0.05)。结论 采用亚安培南、西司他丁与莫西沙星联合方案用药后,药物肺组织穿透能力及抗菌活性强,并具有抗菌谱广的优势,生物利用率高,对于患者而言可以促使其快速的达到血药浓度的稳定状态,不仅半衰期长,还具有药效持久的优势,故而联合用药的应用效果显著。而且,采用亚安培南、西司他丁与莫西沙星联合方案对老年重症肺炎患者的病情改善具有积极作用,还能够控制不良反应,进一步提升治疗安全性,值得临床推广应用。Objective To study the effect of the combination regimen of imipenem, cilastatin and moxifloxacin in the treatment of elderly patients with severe pneumonia to further improve the clinical treatment efficacy. Methods The elderly patients with severe pneumonia admitted from January 2019 to December 2019 were selected as the study object. Through retrospective analysis, 68 patients were randomly divided into groups to investigate on the premise of fairness. The patients in the control group were treated with routine antibiotics, while those in the observation group were treated with combination of imipenem, cilastatin and moxifloxacin. Results In terms of treatment quality, the total effective rate of the observation group was 91.18%, and that of the control group was 79.41%. There was a significant difference between the two groups(P<0.05). At the same time, in terms of hospitalization time, the observation group was(10.20±3.10) d, while the control group was(15.60±4.20) d, the difference was statistically significant(P<0.05). In addition, the changes of liver and kidney function were compared, that is, the alanine aminotransferase and serum creatinine levels in the observation group were(34.49±6.55) U/L and(81.45±16.14) μmol/L, respectively, while those in the control group were(33.85±5.42) U/L and(82.49±15.49) μmol/L, the difference was not statistically significant(P>0.05). In terms of white blood cell count, serum C-reactive protein and procalcitonin index, the improvement effect of the patients in the observed group was better than that of the control group, and the contrast difference was significant(P<0.05). Finally, the incidence of adverse events in the observation group was 2.94%(1/34), significantly lower than that in the control group 8.82%(3/34), the difference was statistically significant(P<0.05). Conclusion After the use of imipenem, cilastatin and moxifloxacin combination regimen, the drug lung tissue penetration ability and antibacterial activity is strong, and has the advantages of wide

关 键 词：亚安培南 西司他丁 莫西沙星 老年重症肺炎 临床效果 

分 类 号：R563.1[医药卫生—呼吸系统]